These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9989208)

  • 1. Papillomaviruses: prophylactic vaccine prospects.
    Lowy DR; Schiller JT
    Biochim Biophys Acta; 1999 Jan; 1423(1):M1-8. PubMed ID: 9989208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillomavirus-like particle vaccines.
    Schiller JT; Lowy DR
    J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.
    Baud D; Ponci F; Bobst M; De Grandi P; Nardelli-Haefliger D
    J Virol; 2004 Dec; 78(23):12901-9. PubMed ID: 15542642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillomavirus-like particles for serology and vaccine development.
    Kirnbauer R
    Intervirology; 1996; 39(1-2):54-61. PubMed ID: 8957670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Papillomavirus-like particle based vaccines: cervical cancer and beyond.
    Schiller JT; Lowy DR
    Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
    Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
    J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, properties and applications of papillomavirus-like particles.
    Sapp M; Volpers C; Streeck RE
    Intervirology; 1996; 39(1-2):49-53. PubMed ID: 8957669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-papillomavirus vaccines and prevention of cervical cancer: progress and prospects].
    Hantz S; Alain S; Denis F
    Presse Med; 2005 Jun; 34(10):745-53. PubMed ID: 16026130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.
    Stanley MA
    Expert Rev Vaccines; 2003 Jun; 2(3):381-9. PubMed ID: 12903803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillomaviruses and cervical cancer: pathogenesis and vaccine development.
    Lowy DR; Schiller JT
    J Natl Cancer Inst Monogr; 1998; (23):27-30. PubMed ID: 9709299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine.
    Goldie SJ; Grima D; Kohli M; Wright TC; Weinstein M; Franco E
    Int J Cancer; 2003 Oct; 106(6):896-904. PubMed ID: 12918067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.